EP 1178047 B1 20040225 - Diazabicyclooctane derivatives and therapeutic uses thereof
Title (en)
Diazabicyclooctane derivatives and therapeutic uses thereof
Title (de)
Diazacyclooctanverbindungen und ihre therapeutische Verwendung
Title (fr)
Dérivées des composés diazacycloactanes et leur usage thérapeutique
Publication
Application
Priority
US 22270600 P 20000803
Abstract (en)
[origin: EP1178047A1] The present invention provides diazabicyclooctane derivatives of formula (I): <CHEM> and pharmaceutically acceptable salts thereof, wherein the group <CHEM> represents <CHEM> R<1> and R<2> are selected independently from H, (C1-C6)alkyl, (C1-C6)fluoroalkyl, halogen (e.g., F, Cl, Br, I), cyano, nitro, O-(C1-C6)alkyl, O-(C1-C6)fluoroalkyl, -NHC(O)R<4> and -OR<4>, where R<4> and R<5> are selected independently from H, (C1-C6)alkyl, and a 5- to 7-membered aryl or heteroaryl ring, or R<1> and R<2> together with the atoms to which they are attached, form a carbocyclic 5- or 6-membered ring or a heterocyclic 5- or 6-membered ring; and R<3> is selected from the group consisting of H, (C1-C6)alkyl, (CH2)m-aryl or (CH2)m-heteroaryl, wherein m is an integer from 1 to 4, each aryl or heteroaryl group optionally substituted with Cl, Br, CN, CF3, O-(C1-C6)alkyl, (C1-C6)alkyl, sulfonyl(C1-C6)alkyl, -CO(C1-C6)alkyl, -CONH2, -CONH(C1-C6)alkyl, -CON((C1-C6)alkyl)2, or CH(OH)(C1-C6)alkyl. The invention also relates to pharmaceutical compositions of a compound of formula (I), and methods of use thereof in the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to processes for the preparation of compounds of formula (I) and intermediates useful therefor.
IPC 1-7
IPC 8 full level
A61K 31/4985 (2006.01); A61P 1/08 (2006.01); A61P 3/04 (2006.01); A61P 7/02 (2006.01); A61P 15/00 (2006.01); A61P 25/00 (2006.01); A61P 25/08 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 25/32 (2006.01); A61P 25/34 (2006.01); A61P 25/36 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01); C07D 471/08 (2006.01); C07D 487/08 (2006.01)
CPC (source: EP US)
A61P 1/08 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 7/02 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 25/30 (2017.12 - EP); A61P 25/32 (2017.12 - EP); A61P 25/34 (2017.12 - EP); A61P 25/36 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 471/08 (2013.01 - EP US); C07D 487/08 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
EP 1178047 A1 20020206; EP 1178047 B1 20040225; AT E260281 T1 20040315; BR 0103180 A 20020326; CA 2354605 A1 20020203; CA 2354605 C 20060530; DE 60102106 D1 20040401; DE 60102106 T2 20040715; DK 1178047 T3 20040524; ES 2211738 T3 20040716; JP 2002088084 A 20020327; JP 3825657 B2 20060927; MX PA01007955 A 20020806; PT 1178047 E 20040531; TR 200400510 T4 20040823; US 2002068748 A1 20020606; US 6531468 B2 20030311
DOCDB simple family (application)
EP 01306313 A 20010723; AT 01306313 T 20010723; BR 0103180 A 20010801; CA 2354605 A 20010801; DE 60102106 T 20010723; DK 01306313 T 20010723; ES 01306313 T 20010723; JP 2001235227 A 20010802; MX PA01007955 A 20010803; PT 01306313 T 20010723; TR 200400510 T 20010723; US 92058701 A 20010801